Use of sputum eosinophil counts to guide management in children with severe asthma

Thorax

Volumn 67, Issue 11, 2012, Pages 1015-1016

  Fleming, Louise ^a   Bush, Andrew ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; LONG ACTING DRUG;

ADRENAL INSUFFICIENCY; ASTHMA; CLINICAL PROTOCOL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; EOSINOPHIL COUNT; HUMAN; LETTER; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SPUTUM ANALYSIS; TREATMENT RESPONSE;

EID: 84868198794     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201930     Document Type: Letter

References (5)

1. Fleming L, Wilson N, Regamey N, et al. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012;67:193-8.
2. Pavord ID, Gibson PG. Inflammometry: the current state of play. Thorax 2012;67:191-2.
3. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996;348:27-9. 6-7. (Pubitemid 26237242)
4. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61. (Pubitemid 35440691)
5. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011;378:983-90.